LPAR6 Participates in Neuropathic Pain by Mediating Astrocyte Cells via ROCK2/NF-κB Signal Pathway
- 20 March 2024
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 61 (10) , 8402-8413
Abstract
Neuropathic pain (NPP) is a common type of chronic pain. Glial cells, including astrocytes (AS), are believed to play an important role in the progression of NPP. AS cells can be divided into various types based on their expression profiles, among which A1 and A2 types have clear functions. A1-type AS cells are neurotoxic, while A2-type AS cells exert neuroprotective functions. Some types of lysophosphatidic acid receptors (LPAR) have been shown to play a role in NPP. However, it remains unclear how AS cells and LPAR6 affect the occurrence and progression of NPP. In this study, we established a mouse model of chronic constriction injury (CCI) to simulate NPP. It was found that the expression of LPAR6 in AS cells of the spinal dorsal horn was increased in the CCI model, and the thresholds of mechanical and thermal pain were elevated after knocking out LPAR6, indicating that LPAR6 and AS cells participated in the occurrence of NPP. The experiment involved culturing primary AS cells and knocking down LPAR6 by Lentivirus. The results showed that the NF-κB signal pathway was activated and the number of A1-type AS cells increased in the CCI model. However, LPAR6 knockdown inhibited the NF-κB signal pathway and A1-type AS cells. The results of the mRNA sequencing and immunoprecipitation test indicate an interaction between LPAR6 and ROCK2. Inhibiting ROCK2 by Y-27632 increased mechanical and thermal pain thresholds and alleviated NPP at the molecular level. The study presents evidence that LPAR6 activates the NF-κB pathway through ROCK2 and contributes to the progression of NPP by increasing A1-type AS and decreasing A2-type AS. This suggests that LPAR6 could be a potential therapeutic target for alleviating NPP. Clinical applications that are successful can offer new therapeutic options, enhance the quality of life for patients, and potentially uncover new mechanisms for pain modulation.Keywords
Funding Information
- National Natural Science Foundation of China (82171220, 82101445)
- Naval Project (AHJ21J003)
This publication has 38 references indexed in Scilit:
- ROCK inhibitor attenuates carbon blacks‐induced pulmonary fibrosis in mice via Rho/ROCK/NF‐kappa B pathwayEnvironmental Toxicology, 2021
- Estrogen Attenuates Traumatic Brain Injury by Inhibiting the Activation of Microglia and Astrocyte-Mediated Neuroinflammatory ResponsesMolecular Neurobiology, 2020
- LPA Induces Keratinocyte Differentiation and Promotes Skin Barrier Function through the LPAR1/LPAR5-RHO-ROCK-SRF AxisJournal of Investigative Dermatology, 2019
- N‐myc downstream‐regulated gene 2 controls astrocyte morphology via Rho‐GTPase signalingJournal of Cellular Physiology, 2019
- Alkannin attenuates lipopolysaccharide‐induced lung injury in mice via Rho/ROCK/NF‐κB pathwayJournal of Biochemical and Molecular Toxicology, 2019
- Lysophosphatidic acid receptor, LPA6, regulates endothelial blood-brain barrier function: Implication for hepatic encephalopathyBiochemical and Biophysical Research Communications, 2018
- Inhibition of AGEs/RAGE/Rho/ROCK pathway suppresses non-specific neuroinflammation by regulating BV2 microglial M1/M2 polarization through the NF-κB pathwayJournal of Neuroimmunology, 2017
- Lysophosphatidic acid (LPA) signaling via LPA 4 and LPA 6 negatively regulates cell motile activities of colon cancer cellsBiochemical and Biophysical Research Communications, 2017
- Crocetin ester improves myocardial ischemia via Rho/ROCK/NF-κB pathwayInternational Immunopharmacology, 2016
- Ethical guidelines for investigations of experimental pain in conscious animalsPain, 1983